Table 2 Best objective response to treatment

From: Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients

 

Total (56)

 

No.

%

Complete response (CR)

3

5

Partial response (PR)

26

46

Stable disease (SD)

10

18

Progressive disease (PD)

9 (12)a

16 (21%)a

Not assessable (NA)b

8 (5)a

14 (9%)a

  1. aThree patients were not assessable by our criteria, but displayed clinical disease progression that was not objectively validated (two received only two treatment cycles before clinical progression and one received four cycles and only one assessment before clinical progression).
  2. bNot assessable patients were one patient who had clinical disease progression after two cycles but was too unwell to repeat imaging, five patients who received fewer than planned cycles of therapy, one patient whose scans were lost and was thus not assessed properly at cycle 7, and one patient who received only one assessment before clinical progression.